Sign in
4

Changes in Ownership

Protalix BioTherapeutics, Inc. Filed Acc 0001385115-08-000001

VP, Chief Financial Officer sold 33,300 shares at $3.18 ($105,761)

  • VP, Chief Financial Officer gave up 26,176 shares (to pay taxes)
  • VP, Chief Financial Officer acquired 86,176 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Yossi Maimon VP, Chief Financial Officer 2008-02-22 Option exercise +86,176 $0.97 $83,763 86,176 I: show line 1 in the form
Yossi Maimon VP, Chief Financial Officer 2008-02-22 Shares withheld for taxes −26,176 $3.20 $83,763 60,000 I: show line 2 in the form
Yossi Maimon VP, Chief Financial Officer 2008-02-25 Sale −33,300 $3.18 $105,761 26,700 I: show line 3 in the form
Open-market sales · 33,300 sh · avg $3.18 · $105,761

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Yossi Maimon VP, Chief Financial Officer 2008-02-22 Option exercise · Stock Options (Right to Buy) −86,176 533,796 D: show line 4 in the form
Loading xslF345X02/primary_doc.xml…